Newsletter | November 10, 2020

11.10.20 -- How To Predict And Prepare For Illusive Cell Therapy Issues

 
Tumor-Infiltrating Lymphocytes: What, Why, And How
 

As we’ve begun to slowly understand and unlock the complexities of immune mechanisms through technology, we’ve found better ways to fight disease. Immunotherapy of cancer is a prime example. Here, we focus on targeted, highly personalized cancer therapies called tumor-infiltrating lymphocytes.

Developing TIL Therapies: Sample Collection And Processing
 

While it has been advanced over many years, the process of developing tumor-infiltrating lymphocyte (TIL) therapies still suffers from certain challenges. This article attempts to lay bare some of these challenges and discuss how novel technological solutions can help overcome them.

Standardizing The Vein-To-Vein Logistics Workflow To Reach More Patients
 

The supply chain and logistics for cell and gene therapies is especially critical to ensure the right patient gets the right treatment at the right time. Collaboration is the key to solving challenges such as data management and process variability, as stakeholders work toward a common goal — getting these lifesaving treatments to the people who need them.

6 Misconceptions About Automating Cell Therapy Manufacturing
 

Cell therapies have burst onto the market with great promise to improve patient treatment options and alter clinical care. To help you move into a digitized world, here are six common misconceptions that can potentially hinder your ability to successfully execute a manufacturing execution system (MES) for cell therapy.

Key Considerations For Cryogenic Preservation And T Cell Viability
 

Cryopreservation provides critical protection for cell therapies by minimizing genetic changes. But cooling too slowly or quickly risks diminishing cell viability upon thaw. This article discusses the importance of controlled-rate cryopreservation, illustrating how mammalian cells change when frozen, and describes concrete cryopreservation strategies.